Home > Boards > US Listed > Medical - Drugs > Merck & Co. Inc. (MRK)

MRK/AZN—Lynparza shows statsig-superior OS to hormonal agents (Xtandi,

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 739
Posts 112,978
Boards Moderated 16
Alias Born 09/05/02
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 3:45:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 2:46:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 2:46:07 PM
Merck Animal Health Completes Acquisition of U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals Business Wire - 7/2/2020 2:00:00 AM
Merck and Ridgeback Bio Announce Closing of Collaboration and Licensing Transaction Business Wire - 7/1/2020 4:30:00 PM
Merck to Hold Second-Quarter 2020 Sales and Earnings Conference Call on July 31 Business Wire - 7/1/2020 6:45:00 AM
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H ... Business Wire - 6/29/2020 4:20:00 PM
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamo... Business Wire - 6/24/2020 5:29:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/24/2020 4:21:55 PM
Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual Business Wire - 6/24/2020 6:45:00 AM
Annual Report of Employee Stock Plans (11-k) Edgar (US Regulatory) - 6/23/2020 2:18:55 PM
Merck Announces That V114, Its Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety & Immunogenicity Objectiv... Business Wire - 6/22/2020 6:45:00 AM
Merck’s KEYTRUDA® (pembrolizumab) Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metasta... Business Wire - 6/22/2020 6:30:00 AM
Merck Completes Acquisition of Themis Business Wire - 6/19/2020 8:29:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/18/2020 5:00:08 PM
Merck Animal Health Completes Acquisition of Quantified Ag® Business Wire - 6/17/2020 4:30:00 PM
FDA Approves Second Biomarker-Based Indication for Merck’s KEYTRUDA® (pembrolizumab), Regardless of Tumor Type Business Wire - 6/17/2020 6:45:00 AM
Merck Prices $4.5 Billion Debt Offering Business Wire - 6/17/2020 6:30:00 AM
Merck & Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Ty... Business Wire - 6/16/2020 1:15:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/16/2020 9:05:45 AM
Merck Announces Call for Proposals for Second Cohort of Safer Childbirth Cities, Expanding Maternal Health Support Across US ... Business Wire - 6/15/2020 8:00:00 AM
FDA Approves Merck’s GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers Business Wire - 6/12/2020 6:40:00 PM
Merck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy & in Combination with... Business Wire - 6/9/2020 4:05:00 PM
FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, & relebactam) for the Treatment of Adults with Hospital-Acquired &... Business Wire - 6/5/2020 6:50:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/2/2020 5:44:34 PM
DewDiligence Member Level  Friday, 04/24/20 12:51:00 PM
Re: None
Post # of 544 
MRK/AZN—Lynparza shows statsig-superior OS to hormonal agents (Xtandi, Zytiga) in the phase-3 PROFOUND study in second-line CRPC with certain genetic mutations:

https://www.businesswire.com/news/home/20200424005205/en

Lynparza is the only PARP inhibitor to show an OS benefit in this setting.

The PROFOUND study met its primary endpoint of radiographic PFS in Aug 2019, and the resulting NDA and MAA are currently under FDA and EMA review.

A trial of Lynparza in first-line CRPC is in progress with results expected in 2021.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist